 HERZLIYA, Israel, March 08, 2021 GLOBE NEWSWIRE -- PainReform Ltd. Nasdaq: PRFX PainReform or the Company, a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into securities purchase agreements with certain institutional investors to raise approximately 6.0 million through the private placement of 1,304,346 ordinary shares and accompanying warrants to purchase an aggregate of up to 652,173 ordinary shares at a combined purchase price of 4.60 per share and accompanying warrant. The warrants will be exercisable immediately at an exercise price of 4.60 per share and will expire five and a half years from the date of issuance. The closing of the private placement is expected to occur on March 10, 2021, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreements. 